## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.12 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-10.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($790.76)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. McKesson’s Advancing Community Oncology Report Charts a New Era of Innovation for Biopharma and Community Care**
- Source: 01net | 20251201T160617 | Bullish | Relevance: 98%
- McKesson Corporation has released its first-ever Advancing Community Oncology Report, highlighting trends and opportunities in community-based oncology. The report, based on surveys and conference insights, identifies key areas for biopharma and community practices to collaborate, including accelerating precision medicine, expanding clinical trial access, and preparing for technology-driven care. The goal is to strengthen the community oncology ecosystem and improve patient access to innovative therapies.

**2. McKesson’s Advancing Community Oncology Report Charts a New Era of Innovation for Biopharma and Community Care**
- Source: Business Wire | 20251201T160626 | Bullish | Relevance: 98%
- McKesson Corporation announced the publication of its first Advancing Community Oncology Report, detailing trends and opportunities in community-based oncology. The report highlights strategies for biopharma and community practices to accelerate precision medicine, expand clinical trial access, and prepare for technology-driven care, based on insights from over 200 surveyed oncologists and staff, and industry experts. Key findings emphasize the need for collaboration to address challenges like keeping pace with innovations and accessing clinical trials, ultimately aiming to improve patient outcomes in community settings.

**3. Is There Opportunity in Henry Schein After 18% Rally and Digital Dentistry Expansion?**
- Source: Simply Wall Street | 20251201T045231 | Neutral | Relevance: 63%
- Henry Schein's stock recently rallied 18%, sparking debate on its future growth and risk. The company shows a strong valuation score of 5 out of 6 according to Simply Wall St's valuation checks, and a Discounted Cash Flow (DCF) analysis suggests it is significantly undervalued by 57.2%. Its Price-to-Earnings (PE) ratio is currently 22.45x, suggesting it is about fairly valued when compared to its tailored "Fair Ratio" of 24.99x.

**4. What Recent Specialty Pharma Moves Mean for Cardinal Health’s Stock Valuation**
- Source: Simply Wall Street | 20251202T193655 | Neutral | Relevance: 61%
- This article analyzes Cardinal Health's (NYSE:CAH) stock valuation following its expansion into specialty pharmaceuticals. The company's stock has seen significant growth, with a 76.2% year-to-date increase. Using discounted cash flow (DCF) analysis, Simply Wall St suggests Cardinal Health is undervalued by 55.0%, while its P/E ratio indicates it is "about right" given its financial profile and potential.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-10.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $101.1B |
| Beta | 0.38 |
| 52W Range | $558.13 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 18.9 |
| Current P/E | 21.5 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.2% to -4.8% (-10.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.8pp (needs >4.0% for momentum thesis). AM_20 at -3.2% indicates price below own 20MA trend. Underperforming sector by 4.6pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.15x) but short-term weakness (below SMA20). MACD histogram bearish (-4.61), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.84% (CS: 13) | Weak |
| RSI_14 | 45.9 | Neutral |
| MACD Histogram | -4.61 | Bearish |
| vs SMA20 | 0.968x | Below |
| vs SMA50 | 1.026x | Above |
| vs SMA200 | 1.152x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $829.70
- **Stop Loss:** $790.76 (4.7% risk)
- **Target:** $907.58 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 25
- **Position Value:** $20,742.50
- **Portfolio %:** 20.74%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*